Page last updated: 2024-08-07 16:21:43
Adenosine receptor A3
An adenosine receptor A3 that is encoded in the genome of rat. [OMA:P28647, PRO:DNx]
Synonyms
TGPCR1
Research
Bioassay Publications (42)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 2 (4.76) | 18.7374 |
| 1990's | 13 (30.95) | 18.2507 |
| 2000's | 16 (38.10) | 29.6817 |
| 2010's | 9 (21.43) | 24.3611 |
| 2020's | 2 (4.76) | 2.80 |
Compounds (109)
Drugs with Potency Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| ml106 | Rattus norvegicus (Norway rat) | Potency | 0.0708 | 1 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.0631 | 1 | 0 |
| N-(2-furanylmethyl)-6-(3-methoxyphenyl)-N-methyl-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.3548 | 1 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.1122 | 1 | 0 |
| 6-(2-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 0 |
| 6-(3-furanyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.2512 | 1 | 0 |
| 6-(3-pyridinyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1 | 0 |
| 6-(3-furanyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.2239 | 1 | 0 |
| 6-(3-methoxyphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 2.5119 | 1 | 0 |
| 6-(2-chlorophenyl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1 | 0 |
| 6-(3-methoxyphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 1.0000 | 1 | 0 |
| 6-(3-furanyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.5623 | 1 | 0 |
| N-[(3-methylphenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 2.8184 | 1 | 0 |
| N-(2-furanylmethyl)-N-methyl-6-(1-methyl-5-indolyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 14.1254 | 1 | 0 |
| 6-(2-chlorophenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1 | 0 |
| 6-(3-methoxyphenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1 | 0 |
| 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.5623 | 1 | 0 |
| 6-(2-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1 | 0 |
| 6-(3-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 3.9811 | 1 | 0 |
| 6-(3-pyridinyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 1 | 0 |
| 6-(3-methylphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1 | 0 |
| 6-(1-methyl-5-indolyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 14.1254 | 1 | 0 |
| 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.1413 | 1 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 1.7783 | 1 | 0 |
| 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.3981 | 1 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-[(3-fluorophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.1413 | 1 | 0 |
| 6-(3-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 4.4668 | 1 | 0 |
| 6-(3-methylphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.1259 | 1 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(2-chlorophenyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 14.1254 | 1 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 1.2589 | 1 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(3-pyridinyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 7.0795 | 1 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(3-furanyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.7079 | 1 | 0 |
| 6-(2-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 8.9125 | 1 | 0 |
| 6-(3-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 0 |
| 6-(3-methoxyphenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.8913 | 1 | 0 |
| N-[(4-methyl-2-thiophenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 4.4668 | 1 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.1585 | 1 | 0 |
| 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.4467 | 1 | 0 |
| 6-(3-furanyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | Rattus norvegicus (Norway rat) | Potency | 0.5623 | 1 | 0 |
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| 1,3-dipropyl-8-cyclopentylxanthine | Rattus norvegicus (Norway rat) | IC50 | 0.0038 | 1 | 1 |
| 1,3-dipropyl-8-cyclopentylxanthine | Rattus norvegicus (Norway rat) | Ki | 3.2950 | 2 | 2 |
| 1,3-dipropyl-8-(4-sulfophenyl)xanthine | Rattus norvegicus (Norway rat) | Ki | 90.1000 | 1 | 1 |
| enprofylline | Rattus norvegicus (Norway rat) | Ki | 65.0000 | 1 | 1 |
| 8-phenyltheophylline | Rattus norvegicus (Norway rat) | Ki | 0.5000 | 1 | 1 |
| theophylline | Rattus norvegicus (Norway rat) | Ki | 45.4056 | 8 | 9 |
| caffeine | Rattus norvegicus (Norway rat) | Ki | 56.6667 | 6 | 6 |
| cgs 15943 | Rattus norvegicus (Norway rat) | IC50 | 0.0607 | 1 | 1 |
| 1-methyl-3-isobutylxanthine | Rattus norvegicus (Norway rat) | Ki | 5.1417 | 4 | 6 |
| n 0840 | Rattus norvegicus (Norway rat) | Ki | 1,330.0000 | 1 | 1 |
| nicardipine | Rattus norvegicus (Norway rat) | Ki | 11.0000 | 1 | 1 |
| 8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine | Rattus norvegicus (Norway rat) | Ki | 29.0000 | 1 | 1 |
| 2-chloroadenosine | Rattus norvegicus (Norway rat) | Ki | 0.9438 | 5 | 5 |
| toyocamycin | Rattus norvegicus (Norway rat) | IC50 | 3,235,940.0000 | 1 | 1 |
| nsc 65346 | Rattus norvegicus (Norway rat) | IC50 | 2,137,960.0000 | 1 | 1 |
| cladribine | Rattus norvegicus (Norway rat) | Ki | 207.0000 | 1 | 1 |
| hyaluronoglucosaminidase | Rattus norvegicus (Norway rat) | Ki | 0.7420 | 1 | 1 |
| 3-deazaadenosine | Rattus norvegicus (Norway rat) | Ki | 61.7000 | 1 | 1 |
| adenosine | Rattus norvegicus (Norway rat) | Ki | 0.1000 | 1 | 1 |
| 3'-amino-3'-deoxyadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0840 | 1 | 1 |
| aristeromycin | Rattus norvegicus (Norway rat) | Ki | 110.0000 | 2 | 2 |
| metrifudil | Rattus norvegicus (Norway rat) | Ki | 0.1990 | 2 | 2 |
| n(6)-benzyladenosine | Rattus norvegicus (Norway rat) | Ki | 0.1200 | 1 | 1 |
| phenylisopropyladenosine | Rattus norvegicus (Norway rat) | IC50 | 0.0497 | 1 | 2 |
| phenylisopropyladenosine | Rattus norvegicus (Norway rat) | Ki | 0.0166 | 5 | 5 |
| bromotubercidin | Rattus norvegicus (Norway rat) | IC50 | 8,317,640.0000 | 1 | 1 |
| 5-iodotubercidin | Rattus norvegicus (Norway rat) | IC50 | 38,904,500.0000 | 1 | 1 |
| 5-chlorotubercidin | Rattus norvegicus (Norway rat) | IC50 | 4,786,300.0000 | 1 | 1 |
| 5'-n-methylcarboxamideadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0675 | 2 | 2 |
| 3,7-dimethyl-1-propargylxanthine | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| n-methyladenosine | Rattus norvegicus (Norway rat) | Ki | 6.4000 | 1 | 1 |
| bw a1433u | Rattus norvegicus (Norway rat) | Ki | 45.1000 | 1 | 1 |
| n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0011 | 12 | 12 |
| 2-chloro-n(6)cyclopentyladenosine | Rattus norvegicus (Norway rat) | Ki | 0.2370 | 3 | 4 |
| 8-(4-carboxymethyloxy)phenyl-1,3-dipropylxanthine | Rattus norvegicus (Norway rat) | Ki | 75.7000 | 2 | 2 |
| bw a522 | Rattus norvegicus (Norway rat) | Ki | 1.1700 | 1 | 1 |
| 2-hexynyladenosine-5'-n-ethylcarboxamide | Rattus norvegicus (Norway rat) | Ki | 0.0256 | 1 | 1 |
| zm 241385 | Rattus norvegicus (Norway rat) | IC50 | 0.0949 | 1 | 1 |
| mrs 1067 | Rattus norvegicus (Norway rat) | Ki | 5.5000 | 1 | 1 |
| mrs 1191 | Rattus norvegicus (Norway rat) | Ki | 1.4200 | 2 | 2 |
| mrs 1220 | Rattus norvegicus (Norway rat) | Ki | 0.0100 | 1 | 1 |
| 5'-deoxyadenosine | Rattus norvegicus (Norway rat) | Ki | 2.8300 | 1 | 1 |
| 2'-amino-2'-deoxyadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0100 | 1 | 1 |
| adenosine-5'-(n-ethylcarboxamide) | Rattus norvegicus (Norway rat) | Ki | 0.1553 | 7 | 7 |
| fludarabine | Rattus norvegicus (Norway rat) | Ki | 10.4000 | 1 | 1 |
| n(6)-cyclopentyladenosine | Rattus norvegicus (Norway rat) | Ki | 0.2178 | 4 | 4 |
| 3-(methylthio)-4-oxo-6,7-dihydro-5H-2-benzothiophene-1-carboxylic acid ethyl ester | Rattus norvegicus (Norway rat) | Ki | 15.2000 | 1 | 1 |
| 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide | Rattus norvegicus (Norway rat) | Ki | 0.0004 | 8 | 8 |
| 2-((2-aminoethylamino)carbonylethylphenylethylamino)-5'-n-ethylcarboxamidoadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0500 | 1 | 1 |
| 2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine | Rattus norvegicus (Norway rat) | Ki | 0.5840 | 2 | 2 |
| mrs 1523 | Rattus norvegicus (Norway rat) | Ki | 0.2066 | 5 | 5 |
| mre 3008-f20 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| psb 1115 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| n-(1-methyl-2-phenylethyl)adenosine, (s)-isomer | Rattus norvegicus (Norway rat) | Ki | 0.2660 | 5 | 5 |
| bw a1433 | Rattus norvegicus (Norway rat) | Ki | 15.0000 | 2 | 2 |
| mrs 1754 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| bay-k-8644 | Rattus norvegicus (Norway rat) | Ki | 6.2000 | 1 | 1 |
| 1-aminoadenosine | Rattus norvegicus (Norway rat) | Ki | 16.9000 | 1 | 1 |
| 5'-amino-5'-deoxyadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0100 | 1 | 1 |
| n(6)-cyclohexyladenosine | Rattus norvegicus (Norway rat) | IC50 | 0.0024 | 1 | 1 |
| n(6)-cyclohexyladenosine | Rattus norvegicus (Norway rat) | Ki | 0.0070 | 1 | 1 |
| mrs 1097 | Rattus norvegicus (Norway rat) | Ki | 4.1600 | 1 | 1 |
| 3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine | Rattus norvegicus (Norway rat) | Ki | 0.0013 | 2 | 2 |
| vuf 8504 | Rattus norvegicus (Norway rat) | Ki | 4.2000 | 1 | 1 |
| n(6)-(2,2-diphenylethyl)adenosine | Rattus norvegicus (Norway rat) | Ki | 0.5390 | 2 | 2 |
| n-cyclopropyl adenosine-5'-carboxamide | Rattus norvegicus (Norway rat) | Ki | 1.2811 | 5 | 5 |
| sch 442416 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1 | 1 |
| mrs 3558 | Rattus norvegicus (Norway rat) | Ki | 0.0010 | 2 | 2 |
| psb 36 | Rattus norvegicus (Norway rat) | Ki | 6.5000 | 1 | 1 |
| lj 529 | Rattus norvegicus (Norway rat) | Ki | 0.0008 | 1 | 1 |
| psb603 | Rattus norvegicus (Norway rat) | IC50 | 0.0007 | 1 | 1 |
| psb 11 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 2 | 2 |
Drugs with Activation Measurements
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| zm 241385 | Rattus norvegicus (Norway rat) | INH | 10.0000 | 1 | 1 |
Fluorescent-Labeled Selective Adenosine AJournal of medicinal chemistry, , 05-24, Volume: 61, Issue:10, 2018
Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , Sep-30, Volume: 37, Issue:20, 1994
[no title available]European journal of medicinal chemistry, , Jan-15, Volume: 186, 2020
2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists.Bioorganic & medicinal chemistry, , Mar-15, Volume: 18, Issue:6, 2010
1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.Journal of medicinal chemistry, , Jul-09, Volume: 52, Issue:13, 2009
Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
[no title available]European journal of medicinal chemistry, , Jan-15, Volume: 186, 2020
Adenosine A2A receptor as a drug discovery target.Journal of medicinal chemistry, , May-08, Volume: 57, Issue:9, 2014
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.Journal of medicinal chemistry, , Mar-31, Volume: 38, Issue:7, 1995
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.Journal of medicinal chemistry, , Jun-01, Volume: 43, Issue:11, 2000
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.Journal of medicinal chemistry, , Mar-31, Volume: 38, Issue:7, 1995
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.Journal of medicinal chemistry, , Mar-31, Volume: 38, Issue:7, 1995
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.Journal of medicinal chemistry, , Mar-14, Volume: 45, Issue:6, 2002
C4-substituted 1-beta-D-ribofuranosylpyrazolo[3,4-d]pyrimidines as adenosine agonist analogues.Journal of medicinal chemistry, , Volume: 26, Issue:11, 1983
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
Design and in Vivo Characterization of AJournal of medicinal chemistry, , 02-14, Volume: 62, Issue:3, 2019
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.Journal of medicinal chemistry, , Mar-04, Volume: 37, Issue:5, 1994
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012
Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Oct-23, Volume: 51, Issue:20, 2008
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.Bioorganic & medicinal chemistry letters, , May-01, Volume: 18, Issue:9, 2008
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor.Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.Journal of medicinal chemistry, , Apr-22, Volume: 42, Issue:8, 1999
Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.Journal of medicinal chemistry, , Aug-13, Volume: 41, Issue:17, 1998
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors.Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , May-12, Volume: 38, Issue:10, 1995
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.Journal of medicinal chemistry, , Mar-31, Volume: 38, Issue:7, 1995
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.Journal of medicinal chemistry, , Mar-04, Volume: 37, Issue:5, 1994
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection.Journal of medicinal chemistry, , Dec-29, Volume: 48, Issue:26, 2005
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.Journal of medicinal chemistry, , Jun-01, Volume: 43, Issue:11, 2000
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors.Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , Sep-30, Volume: 37, Issue:20, 1994
Fluorescent-Labeled Selective Adenosine AJournal of medicinal chemistry, , 05-24, Volume: 61, Issue:10, 2018
Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility.Journal of medicinal chemistry, , Feb-10, Volume: 54, Issue:3, 2011
Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Feb-25, Volume: 42, Issue:4, 1999
Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Aug-01, Volume: 40, Issue:16, 1997
Design and in Vivo Characterization of AJournal of medicinal chemistry, , 02-14, Volume: 62, Issue:3, 2019
Nucleosides and nucleotides. 200. Reinvestigation of 5'-N-ethylcarboxamidoadenosine derivatives: structure-activity relationships for P(3) purinoceptor-like proteins.Journal of medicinal chemistry, , Jan-18, Volume: 44, Issue:2, 2001
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.Journal of medicinal chemistry, , Apr-22, Volume: 42, Issue:8, 1999
Nucleosides and nucleotides. 177. 9-(6,7-dideoxy-beta-D-allo-hept-5- ynofuranosyl)adenine: a selective and potent ligand for P3 purinoceptor-like protein.Journal of medicinal chemistry, , Jul-16, Volume: 41, Issue:15, 1998
Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.Journal of medicinal chemistry, , Aug-13, Volume: 41, Issue:17, 1998
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.Journal of medicinal chemistry, , Mar-31, Volume: 38, Issue:7, 1995
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.Journal of medicinal chemistry, , Mar-04, Volume: 37, Issue:5, 1994
Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection.Journal of medicinal chemistry, , Dec-29, Volume: 48, Issue:26, 2005
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.Journal of medicinal chemistry, , Mar-14, Volume: 45, Issue:6, 2002
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.Journal of medicinal chemistry, , Jun-01, Volume: 43, Issue:11, 2000
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012
Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Oct-23, Volume: 51, Issue:20, 2008
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.Bioorganic & medicinal chemistry letters, , May-01, Volume: 18, Issue:9, 2008
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Design, synthesis and binding affinity of 3'-fluoro analogues of Cl-IB-MECA as adenosine A3 receptor ligands.Bioorganic & medicinal chemistry letters, , Mar-10, Volume: 13, Issue:5, 2003
N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor.Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.Journal of medicinal chemistry, , Sep-26, Volume: 45, Issue:20, 2002
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.Journal of medicinal chemistry, , Apr-22, Volume: 42, Issue:8, 1999
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Selective AACS medicinal chemistry letters, , Apr-14, Volume: 13, Issue:4, 2022
[no title available]European journal of medicinal chemistry, , Jan-15, Volume: 186, 2020
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.Journal of medicinal chemistry, , Sep-26, Volume: 45, Issue:20, 2002
Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.Journal of medicinal chemistry, , Feb-25, Volume: 42, Issue:4, 1999
Selective AACS medicinal chemistry letters, , Apr-14, Volume: 13, Issue:4, 2022
AJournal of medicinal chemistry, , 04-25, Volume: 62, Issue:8, 2019
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.Journal of medicinal chemistry, , Mar-14, Volume: 45, Issue:6, 2002
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors.Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Journal of medicinal chemistry, , Sep-30, Volume: 37, Issue:20, 1994
AJournal of medicinal chemistry, , 04-25, Volume: 62, Issue:8, 2019
Selective AACS medicinal chemistry letters, , Apr-14, Volume: 13, Issue:4, 2022
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.Journal of medicinal chemistry, , Mar-04, Volume: 37, Issue:5, 1994
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.Journal of medicinal chemistry, , Oct-14, Volume: 37, Issue:21, 1994
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Design and in Vivo Characterization of AJournal of medicinal chemistry, , 02-14, Volume: 62, Issue:3, 2019
Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.Journal of medicinal chemistry, , May-10, Volume: 55, Issue:9, 2012
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.Journal of medicinal chemistry, , Apr-22, Volume: 42, Issue:8, 1999
Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.Journal of medicinal chemistry, , Mar-04, Volume: 37, Issue:5, 1994
Adenosine receptors: targets for future drugs.Journal of medicinal chemistry, , Volume: 25, Issue:3, 1982
Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Selective AACS medicinal chemistry letters, , Apr-14, Volume: 13, Issue:4, 2022
[no title available]European journal of medicinal chemistry, , Jan-15, Volume: 186, 2020